(NASDAQ: BMRN), (NASDAQ: CPWR), (NYSE: CVD)

Turning Pennies into dollars: (NASDAQ: BMRN), (NASDAQ: CPWR), (NYSE: CVD)

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://bmrn.realpennies.com

BioMarin Pharmaceutical Inc. (NASDAQ and SWX: BMRN)(February 5, 2008) announced yesterday that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, February 26, at 5:00 p.m. ET (23:00 CET) to discuss fourth quarter and full year 2007 financial results.

U.S. / Canada Dial-in Number: 866.713.8564 International Dial-in Number: 617.597.5312 Participant Code: 79434433 Replay Dial-in Number: 888.286.8010 Replay International Dial-in Number: 617.801.6888 Replay Code: 87203261

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com.A replay of the call will be archived on the site for at least one week following the call.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com.

BioMarin and Naglazyme are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme is a registered trademark of BioMarin/Genzyme LLC.

For more info: http://cpwr.realpennies.com

Compuware Corporation (NASDAQ: CPWR)(February 6, 2008) announced yesterday that it has acquired privately held Hilgraeve, Inc. of Monroe, Mich. This acquisition makes Compuware Covisint the world's largest on-demand collaboration platform for lab and prescription data sharing. Through Hilgraeve technology, physician practices will now enjoy the ability to rapidly connect to Covisint and securely share key patient information, reducing the cost and improving the quality of healthcare.

"As a practicing physician in a rural community for 17 years, I kno that access to key information has always been a barrier to delivering the highest quality and most efficient care," said Dr. Tom Stevenson, Chief Medical Officer for Covisint. "With Covisint, physicians can now receive comprehensive and accurate information about their patients, regardless of geography or technical ability." Hilgraeve has helped enterprises connect complex systems for more than 25 years and has served as a standard part of every Microsoft Windows operating system for the past decade. Recently, the company has focused on solving connectivity problems in the healthcare, automotive and financial industries. In the healthcare industry in particular, physicians use Hilgraeve solutions to connect to practice management systems and to securely communicate with electronic medical records systems and healthcare payers.

"The healthcare industry must control costs and increase efficiency, and we have been working closely with physicians to help achieve this," said Jeff Beamsley, President for Hilgraeve, Inc. "By joining Covisint, we will improve the future of healthcare connectivity and make a tremendously positive impact on both Covisint and the industry." "This acquisition gives Covisint the foremost technology and expertise available to help physicians connect to healthcare providers and payers," said Bob Paul, Covisint President and COO. "Hilgraeve technology complements the Covisint platform and will deliver cost-effective, automated and easily implemented connectivity to physicians around the world." Covisint turns the extended enterprise into a competitive advantage for 45,800 organizations worldwide. Covisint's highly available platform provides an on-demand infrastructure for secure collaboration, interoperability and access to information. Covisint streamlines and automates business processes, globally connecting business communities, organizations and systems in the automotive, manufacturing, healthcare, public sector and financial services industries.

Compuware Corporation maximizes the value IT brings to the business by helping CIOs more effectively manage the business of IT. Compuware solutions accelerate the development, improve the quality and enhance the performance of critical business systems while enabling CIOs to align and govern the entire IT portfolio, increasing efficiency, cost control and employee productivity throughout the IT organization. Founded in 1973, Compuware serves the world's leading IT organizations, including more than 90 percent of the Fortune 100 companies. Learn more about Compuware at http://www.compuware.com/.

For more info: http://cvd.realpennies.com

Covance Inc. (NYSE: CVD)(February 6, 2008) had a Conference with the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference yesterday at 9:20 am ET. Investors may access the webcast of the presentation at http://www.covance.com.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,700 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com